<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337609</url>
  </required_header>
  <id_info>
    <org_study_id>2008P002387</org_study_id>
    <nct_id>NCT01337609</nct_id>
  </id_info>
  <brief_title>Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of the Probiotic Ganeden BC30 (Bacillus Coagulans GBI-30, 6068) in Irritable Bowel Syndrome Comorbid With Major Depressive Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ganeden Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of a nutritional
      supplement, the probiotic bacteria GanedenBC30. Probiotics are live microorganisms which when
      taken in large enough amounts are supposed to provide a health benefit. The investigators
      would like to see whether this supplement can be used as a treatment for Irritable Bowel
      Syndrome (IBS) and Major Depressive Disorder (MDD). Participants in the study will have both
      IBS and MDD. In order to find out if GanedenBC30 is effective in treating IBS and MDD, the
      investigators will compare it to a placebo. About 32 people will take part in this research
      study. About half of these 32 people will take part at Charles River Medical Associates and
      half will take part at Burlington Medical Associates. Participants will be recruited from
      among patients already being seen at Charles River Medical Associates or Burlington Medical
      Associates for their primary care. The study will last for two months, during which time
      participants will make eight study visits and will take either Ganeden BC30 or placebo. The
      investigators hypothesize that subjects treated with the probiotic will have significantly
      better outcomes with regard to depression and IBS symptoms compared to those who receive
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Because the study sponsor chose to discontinue funding for this protocol following a change in
    leadership, the study was terminated early.
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)</measure>
    <time_frame>Administered at each of 8 study visits (every 10 days), Endpoint is Final Visit</time_frame>
    <description>The Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)is a self report measure that addresses depressive symptoms. MDD responders will be defined as those exhibiting a 50% decrease in the QIDS SR at study endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IBS Severity Scoring System (IBS-SSS)</measure>
    <time_frame>Adminsitered at each of 8 study visits (every 10 days), Endpoint is Final Visit</time_frame>
    <description>The IBS-SSS is a validated instrument used to assess common IBS symptoms over the past 10 days including abdominal pain, distention, bowel habit, and global function. The IBS-SSS will be used to assess the absolute change in specific IBS symptoms at endpoint, namely the bloating/distension score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>Administered at each of 8 study visits (every 10 days), Endpoint is Final Visit</time_frame>
    <description>The VAS is a self-administered measure of abdominal pain, discomfort, and bloating. The change in total score from baseline to study endpoint will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate Relief of IBS Pain (AR-IBS)</measure>
    <time_frame>Adminstered at each of 8 visits (every 10 days), Endpoint is Final Visit</time_frame>
    <description>The AR-IBS is a self-administered measure of the adequacy of the relief of IBS pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGI-C) - IBS Symptoms</measure>
    <time_frame>Administered at each of 8 visits (every 10 days), Endpoint is Final Visit</time_frame>
    <description>The PGI-C is a self-administered measure of the degree of improvement in IBS symptoms compared to the first study visit. Degree of improvement in IBS symptoms from first to final visit will be assessed using this scale.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>GanedenBC30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2 will take placebo (sugar pill) for 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ganeden BC30, Sugar pill</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganeden BC30</intervention_name>
    <description>2 billion CFU per capsule; One pill daily for 60 days</description>
    <arm_group_label>GanedenBC30</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (sugar pill)</intervention_name>
    <description>1 pill daily for 60 days</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ganeden BC30, Placebo (sugar pill)</intervention_name>
    <description>Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days</description>
    <arm_group_label>Ganeden BC30, Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to give Informed Consent

          -  Meet criteria for Irritable Bowel Syndrome

          -  Meet criteria for Major Depressive Disorder

          -  Men and women ages 18 to 65

          -  Women of childbearing potential must be using an adequate methods of contraception

          -  Can be on an antidepressant medications, but must have been on the medication for at
             least 8 weeks and at a stable dose for 4 weeks

          -  Can be on medications for IBS, but must have been on medications for at least 8 weeks
             and at a stable dose for 4 weeks

        Exclusion Criteria:

          -  Patients who have failed one or more trials of probiotics for IBS

          -  Patients who report an inadequate response to less than two or more than four adequate
             trails of antidepressant treatments during the current depressive episode at a
             therapeutic dose for an adequate duration

          -  Women who are pregnant or breastfeeding

          -  Patients with &quot;alarm signs&quot; or &quot;red flags&quot; as defined by American Gastroenterological
             Association (AGA) are excluded [6], unless they have been fully evaluated to rule out
             other significant diseases.

          -  Patients with known diagnoses of digestive organic disease, celiac disease and lactose
             intolerance prior to the screening.

          -  Patients who report an inadequate response (less than 50% decrease in depressive
             symptom severity) to less than two or more than four prior adequate trials of
             antidepressant treatments during the current depressive episode (including monotherapy
             treatment and distinct combination regimens) at a therapeutic dose (as defined by the
             MGH-ATRQ) and for an adequate duration (minimum six weeks for any monotherapy).

          -  Patients who report treatment with adjunctive medications to their antidepressant for
             a minimum of four weeks during the current depressive episode.

          -  Patients with a current need for involuntary commitment or who have been hospitalized
             within four weeks of the Screening Visit for the current major depressive episode.

          -  Patients who have received ECT during the current episode.

          -  Patients who have a current Axis I diagnosis of:

        Delirium, dementia, amnestic, or other cognitive disorder; Schizophrenia or other psychotic
        disorder, based on the PDSQ; Bipolar I or II disorder, based on the PDSQ; Patients with a
        clinically significant Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid,
        schizoid, schizotypal or histrionic personality disorder.

          -  Patients experiencing hallucinations, delusions, or any psychotic symptomatology in
             the current depressive episode.

          -  Patients who have met DSM-IV-TR criteria for any significant substance use disorder
             within the past six months, based on the PDSQ.

          -  Patients receiving new onset depression-focused psychotherapy within 6 weeks of
             screening, or at any time during participation in the trial.

          -  Patients who have been previously randomized in a probiotics clinical trial
             (lifetime).

          -  Patients who have participated in any clinical trial with an investigational drug or
             device within the past month.

          -  Patients who, in the opinion of the investigator, are actively suicidal or homicidal
             and at significant risk for suicide or homicide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Fava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burlington Medical Associates</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles River Medical Associates</name>
      <address>
        <city>Westborough</city>
        <state>Massachusetts</state>
        <zip>01581</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://massgeneral.org/depression</url>
    <description>Massachusetts General Hospital Depression Clinical and Research Program Website</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <results_first_submitted>May 29, 2013</results_first_submitted>
  <results_first_submitted_qc>August 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2013</results_first_posted>
  <last_update_submitted>August 7, 2013</last_update_submitted>
  <last_update_submitted_qc>August 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Maurizio Fava, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Bacillus Coagulans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GanedenBC30</title>
          <description>Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Arm 2 will take placebo (sugar pill) for 60 days.</description>
        </group>
        <group group_id="P3">
          <title>Ganeden BC30, Sugar Pill</title>
          <description>Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GanedenBC30</title>
          <description>Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Arm 2 will take placebo (sugar pill) for 60 days.</description>
        </group>
        <group group_id="B3">
          <title>Ganeden BC30, Sugar Pill</title>
          <description>Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)</title>
        <description>The Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)is a self report measure that addresses depressive symptoms. MDD responders will be defined as those exhibiting a 50% decrease in the QIDS SR at study endpoint.</description>
        <time_frame>Administered at each of 8 study visits (every 10 days), Endpoint is Final Visit</time_frame>
        <population>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and this outcome measure was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GanedenBC30</title>
            <description>Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Arm 2 will take placebo (sugar pill) for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Ganeden BC30, Sugar Pill</title>
            <description>Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)</title>
          <description>The Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)is a self report measure that addresses depressive symptoms. MDD responders will be defined as those exhibiting a 50% decrease in the QIDS SR at study endpoint.</description>
          <population>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and this outcome measure was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IBS Severity Scoring System (IBS-SSS)</title>
        <description>The IBS-SSS is a validated instrument used to assess common IBS symptoms over the past 10 days including abdominal pain, distention, bowel habit, and global function. The IBS-SSS will be used to assess the absolute change in specific IBS symptoms at endpoint, namely the bloating/distension score.</description>
        <time_frame>Adminsitered at each of 8 study visits (every 10 days), Endpoint is Final Visit</time_frame>
        <population>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and this outcome measure was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GanedenBC30</title>
            <description>Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Arm 2 will take placebo (sugar pill) for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Ganeden BC30, Sugar Pill</title>
            <description>Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>IBS Severity Scoring System (IBS-SSS)</title>
          <description>The IBS-SSS is a validated instrument used to assess common IBS symptoms over the past 10 days including abdominal pain, distention, bowel habit, and global function. The IBS-SSS will be used to assess the absolute change in specific IBS symptoms at endpoint, namely the bloating/distension score.</description>
          <population>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and this outcome measure was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS)</title>
        <description>The VAS is a self-administered measure of abdominal pain, discomfort, and bloating. The change in total score from baseline to study endpoint will be assessed.</description>
        <time_frame>Administered at each of 8 study visits (every 10 days), Endpoint is Final Visit</time_frame>
        <population>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and this outcome measure was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GanedenBC30</title>
            <description>Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Arm 2 will take placebo (sugar pill) for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Ganeden BC30, Sugar Pill</title>
            <description>Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS)</title>
          <description>The VAS is a self-administered measure of abdominal pain, discomfort, and bloating. The change in total score from baseline to study endpoint will be assessed.</description>
          <population>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and this outcome measure was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adequate Relief of IBS Pain (AR-IBS)</title>
        <description>The AR-IBS is a self-administered measure of the adequacy of the relief of IBS pain.</description>
        <time_frame>Adminstered at each of 8 visits (every 10 days), Endpoint is Final Visit</time_frame>
        <population>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and this outcome measure was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GanedenBC30</title>
            <description>Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Arm 2 will take placebo (sugar pill) for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Ganeden BC30, Sugar Pill</title>
            <description>Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Adequate Relief of IBS Pain (AR-IBS)</title>
          <description>The AR-IBS is a self-administered measure of the adequacy of the relief of IBS pain.</description>
          <population>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and this outcome measure was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change (PGI-C) - IBS Symptoms</title>
        <description>The PGI-C is a self-administered measure of the degree of improvement in IBS symptoms compared to the first study visit. Degree of improvement in IBS symptoms from first to final visit will be assessed using this scale.</description>
        <time_frame>Administered at each of 8 visits (every 10 days), Endpoint is Final Visit</time_frame>
        <population>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and this outcome measure was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GanedenBC30</title>
            <description>Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Arm 2 will take placebo (sugar pill) for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Ganeden BC30, Sugar Pill</title>
            <description>Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change (PGI-C) - IBS Symptoms</title>
          <description>The PGI-C is a self-administered measure of the degree of improvement in IBS symptoms compared to the first study visit. Degree of improvement in IBS symptoms from first to final visit will be assessed using this scale.</description>
          <population>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and this outcome measure was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo for 60 Days</title>
        </group>
        <group group_id="E2">
          <title>GanedenBC30 for 60 Days</title>
        </group>
        <group group_id="E3">
          <title>Placebo for 30 Days, Followed by GanedenBC30 for 30 Days</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarct; residual leg weakness and face drooping</sub_title>
                <description>Unrelated to study treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Labial cyst, constipation, and tension headache</sub_title>
                <description>Unrelated to study treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Unrelated to study treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinus infection</sub_title>
                <description>Unrelated to study treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right flank pain</sub_title>
                <description>Unrelated to study treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and data were not analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Maurizio Fava</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-2513</phone>
      <email>mfava@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

